Idefirix 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
IAIN/0022 
A.5.a - Administrative change - Change in the name 
08/03/2024 
and/or address of a manufacturer/importer 
responsible for batch release 
amended 
on 
Annex II and 
PL 
PSUSA/10870
Periodic Safety Update EU Single assessment - 
28/09/2023 
n/a 
PRAC Recommendation - maintenance 
/202302 
imlifidase 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
R/0014 
Renewal of the marketing authorisation. 
25/05/2023 
17/07/2023 
SmPC 
The CHMP, having reviewed the available information on 
the status of the fulfilment of Specific Obligations and 
having confirmed the positive benefit risk balance, is of the 
opinion that the quality, safety and efficacy of this 
medicinal product continue to be adequately and 
sufficiently demonstrated and therefore recommends the 
renewal of the conditional MA for Idefirix, subject to the 
Specific Obligations and Conditions as laid down in Annex II 
to the opinion. 
II/0015 
B.I.z - Quality change - Active substance - Other 
04/05/2023 
n/a 
variation 
II/0013 
B.II.b.3.c - Change in the manufacturing process of 
14/04/2023 
n/a 
the finished or intermediate product - The product is 
a biological/immunological medicinal product and the 
change requires an assessment of comparability 
IB/0016 
B.II.d.2.d - Change in test procedure for the finished 
12/04/2023 
n/a 
product - Other changes to a test procedure 
(including replacement or addition) 
II/0010 
B.I.b.2.d - Change in test procedure for AS or 
23/03/2023 
n/a 
starting material/reagent/intermediate - Substantial 
change to or replacement of a 
biological/immunological/immunochemical test 
method or a method using a biological reagent for a 
biological AS 
PSUSA/10870
Periodic Safety Update EU Single assessment - 
16/03/2023 
n/a 
PRAC Recommendation - maintenance 
/202208 
imlifidase 
Page 2/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0012 
B.II.b.2.c.1 - Change to importer, batch release 
13/01/2023 
17/07/2023 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
PSUSA/10870
Periodic Safety Update EU Single assessment - 
01/09/2022 
n/a 
PRAC Recommendation - maintenance 
/202202 
imlifidase 
R/0007 
Renewal of the marketing authorisation. 
19/05/2022 
15/07/2022 
SmPC and PL 
The CHMP, having reviewed the available information on 
the status of the fulfilment of Specific Obligations and 
having confirmed the positive benefit risk balance, is of the 
opinion that the quality, safety and efficacy of this 
medicinal product continue to be adequately and 
sufficiently demonstrated and therefore recommends the 
renewal of the conditional MA for Idefirix, subject to the 
Specific Obligations and Conditions as laid down in Annex II 
to the opinion. 
IB/0008 
B.I.b.2.e - Change in test procedure for AS or 
05/04/2022 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
PSUSA/10870
Periodic Safety Update EU Single assessment - 
10/03/2022 
n/a 
PRAC Recommendation - maintenance 
/202108 
imlifidase 
IA/0006/G 
This was an application for a group of variations. 
15/12/2021 
n/a 
A.7 - Administrative change - Deletion of 
Page 3/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturing sites 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
PSUSA/10870
Periodic Safety Update EU Single assessment - 
30/09/2021 
n/a 
PRAC Recommendation - maintenance 
/202102 
imlifidase 
R/0003 
Renewal of the marketing authorisation. 
20/05/2021 
16/07/2021 
SmPC, Annex 
The CHMP, having reviewed the available information on 
II, Labelling 
the status of the fulfilment of Specific Obligations and 
and PL 
having confirmed the positive benefit risk balance, is of the 
opinion that the quality, safety and efficacy of this 
medicinal product continue to be adequately and 
sufficiently demonstrated and therefore recommends the 
renewal of the conditional MA for Idefirix, subject to the 
Specific Obligations and Conditions as laid down in Annex II 
to the opinion. 
IB/0002 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
29/10/2020 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IB/0001 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
05/10/2020 
16/07/2021 
SmPC and PL 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
Page 4/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
